Serving hundreds of leading biopharmaceutical companies globally:

Generated: January 18, 2019

DrugPatentWatch Database Preview

Eculizumab - Biologic Drug Details

« Back to Dashboard

Summary for eculizumab

Tradenames:	1
Patents:	60
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for eculizumab

Pharmacology for eculizumab

Mechanism of Action	Complement Inhibitors

US Patents for eculizumab

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	CureVac AG (Tubingen, DE)	➤ Sign Up	RX	Orphan	search
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	Alexion Pharmaceuticals, Inc. (Cheshire, CT)	➤ Sign Up	RX	Orphan	company
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	Janssen Pharmaceutica NV (Beerse, BE)	➤ Sign Up	RX	Orphan	search
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	Aegis Therapeutics LLC (San Diego, CA)	➤ Sign Up	RX	Orphan	search
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	Teva Pharmaceuticals Industries, Ltd. (Petach-Tikva, IL)	➤ Sign Up	RX	Orphan	search
Alexion Pharm	SOLIRIS	eculizumab	INJECTABLE; IV (INFUSION)	125166	001	2007-03-16	➤ Sign Up	ForSight Vision4, Inc. (Menlo Park, CA)	➤ Sign Up	RX	Orphan	search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patents for eculizumab

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Canada	2807554	➤ Sign Up
Singapore	10201802127U	➤ Sign Up
Poland	2007425	➤ Sign Up
Japan	2013521265	➤ Sign Up
South Africa	201101403	➤ Sign Up
Japan	5902766	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for eculizumab

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0016	France	➤ Sign Up	PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
C/GB10/015	United Kingdom	➤ Sign Up	PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620
2010 00003	Denmark	➤ Sign Up
12/2010	Austria	➤ Sign Up	PRODUCT NAME: ECULIZUMAB
C002/2010	Ireland	➤ Sign Up	SPC002/2010: 20100902, EXPIRES: 20200430
00433	Netherlands	➤ Sign Up	PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey

Citi

Cerilliant

Queensland Health

Federal Trade Commission

Fish and Richardson

Moodys

Argus Health

Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.